IRONWOOD RAISES 2026 GUIDANCE AMID STRONG LINZESS SALES
Ironwood Pharmaceuticals raised total revenue and adjusted EBITDA guidance for 2026, citing strong LINZESS performance, while also repaying convertible notes and initiating a confirmatory Phase 3 trial for apraglutide.
View filing at SEC.gov →